1/14
Looks like no tags are added yet.
Glucoronidation of bile
UGT (UGT1A1)
UGT phenotypes
NM
IM
PM
NM
1/1, 1/36, CC
IM
1/6, *1, 28, 1/37, 1/80, 36/6, 36/28, 36/37, 36/80
PM
6/6, 28/28, 37/37, 80/80

Gilbert Syndrome
poor function of UGT1A1 → reduced bile glucuronidation → jaundice under stress
Atazanavir
treatment of HIV
UGT1A1 inhibitor
strong association between poor metabolizers and jaundice
Guideline for Atazanavir
PM
genotype
28/28, 28/37, 37/37, 80/80, 6/6
decreased UGT1A1 activity → high risk of hyperbilirubinemia
consider alternative agent

NAT2
metabolism of
Hydralazine
Isoniazid
Procainamide
Dapsone
Sulfasalazine
NAT2 phenotypes

Hydralazine ADE
HA, tachycardia, lupus-like syndrome
Hydralazine phenotypes

TPMT and NUDT15 polymorphisms
Azathioprine
6 MP
(immunosuppressants)
Azathioprine and 6-MP ADE
bone marrow suppression
leukopenia
thrombocytopenia
anemia
TPMT and NUDT15 recommendations for starting dose only
2-4 weeks for stabilization in IM, 4-6 weeks in PM
TPMT phenotypes

NUDT15 phenotypes

TPMT and NUDT15 recommended starting dose
